公开资料显示,德曲妥珠单抗(中文名:优赫得,英文商品名:Enhertu)是一款靶向HER2的抗体偶联药物(antibody-drug conjugate,ADC),其在海外获批的适应症包括乳腺癌、胃癌、非小细胞肺癌等。本次为该药首次在中国获批,主要针对的适应症为既往接受过一种或一种以上抗HER2药物治疗的不可切除或转移性HER2阳性成人乳腺癌患者。
26.Fu, Z., et al., Fu, Z., et al.,Antibody drug conjugate: the “biological missile” for targeted cancer therapy.Signal Transduction and Targeted Therapy, 2022.7(1): p. 93.
Trastuzumab deruxtecan(曲妥珠单抗德鲁单抗)是一种抗体偶联药物(Antibody-Drug Conjugate,ADC)。ADC是一类将单克隆抗体与细胞毒性药物通过连接子连接而成的复合物,用于靶向特定的癌细胞。 组成部分 人源化抗 HER2 抗体:Trastuzumab deruxtecan 中的抗体部分是基于曲妥珠单抗(Trastuzumab),能够特异性识别并结合HER2受体。...
Trastuzumab (a type of IgG1 kappa monoclonal antibody) Pertuzumab (a type of monoclonal antibody) Trastuzumab Deruxtecan (a type of HER2-directed antibody drug conjugate) Tucatinib (Tyrosine Kinase HER2 Inhibitor) Ado-trastuzumab emtansine or T-DM1 (a type of HER2-targeted antibody-drug conjugate...
AntibodyDrugConjugateADCTrastuzumabDoxorubicinCardiotoxicityHER2/ErbB2InternalizationSince trastuzumab monotherapy for treatment of breast cancer with HER2/ErbB2 over-expression has been shown to have limited efficacy, combined treatment of trastuzumab with chemotherapy is widely practiced in clinic. However, cert...
In DESTINY-Breast 03, Trastuzumab Deruxtecan, a HER2-specific antibody-drug conjugate, proved superior to T-DM1 in patients with HER2+ metastatic breast cancer progressing on taxane and trastuzumab.1 This study supported its recent approval as second-line therapy in HER2+ metastatic breast cancer....
除了对不同抗体的开发之外,考虑到抗HER2抗体通常与化合物联用,于是罗氏的科学家们试图开发抗体药物偶联物(Antibody-drug conjugate,ADC),这样既可以降低化疗药的副作用,又可以达到比联合施用更好的效果。 Ado-Trastuzumab Emtansine (简称T-DM1,商品名Kadcyla®)就是一种抗体药物偶联物,由曲妥珠单抗和美登素衍生物...
抗体偶联药物(Antibody-Drug Conjugate,简称ADC)是新一代的以大分子为载体的靶向药物,由抗体、连接子和细胞毒性药物三部分构成,利用抗体的靶向性,特异性识别靶细胞表面的抗原,经由网格蛋白介导的内吞作用进入细胞,再通过裂解或酶解的方式,释放细胞毒药物,达到杀伤靶细胞的目的。
Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor. Although trastuzumab is a very active agent in HER2-overexpressing breast cancer, the majority of patients with metastatic HER2-overexpressing breast cancer who init
Trastuzumab emtansine (T-DM1) is a human epidermal growth factor receptor (HER2)-targeted antibody-drug conjugate, composed of trastuzumab, a stable thioether linker, and the potent cytotoxic agent DM1 (derivative of maytansine), in phase III development for HER2-positive cancer. Extensive analysis ...